HPV InfectionNCT05679141
Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits
An observational study of HPV Infection and Cervical Cancer, run by Switch Health Solutions Inc. at 1 site in Canada.
Trial summary
The objective of this study is to validate the of the Evalyn®Brush via self-collection to the standard clinician-collected technique using the BD SurePath™ collection vial and Rovers CombiBrush for detection of Human Papillomavirus (HPV). Read more about this study
- Who is it for?
- Ages 21 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- HPV Infection, Cervical Cancer
- How many people
- 344 participants
- Where
- 1 siteCanada
- Study dates
- 1 Feb 2023to 19 Mar 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Study population are individuals with a cervix who wish to participate in routine screening for HPV and associated risk for cervical cancers.
Who may be able to join
- Participant visiting the study site for a potential OB/GYN purpose
- Participant >= 21 years of age
- Participant has a cervix
Who cannot join
- Currently menstruating
- Currently pregnant or within 3 months following pregnancy
- Utilized vaginal products within past 48 hrs.
- Experiencing any of following symptoms:
- Pain in lower abdomen Fever Unusual or heavy vaginal discharge Pain / bleeding when having intercourse Painful or frequent urination
Trial locations and contacts
1 site in 1 country.
About this study
The objective of this study is to validate the of the Evalyn®Brush via self-collection to the standard clinician-collected technique using the BD SurePath™ collection vial and Rovers CombiBrush for detection of Human Papillomavirus (HPV). This study will validate the sensitivity and specificity of the Evalyn Brush with the future goal of making this testing approach available for self-collection in the future.
Read the detailed description
Cervical cancer is one of the most common female cancers in the world. It has been reported that approximately 1300 Canadians are diagnosed with cervical cancer each year. HPV is a common sexually transmitted DNA virus comprised of more than 100 genotypes. Ninety seven percent (97%) of cervical cancer is attributed to 12 strains of HPV and 70% of cervical cancer cases across the world are attributed to 2 specific strains of the virus (HPV 16 and 18).
The current screening practice in Canada is to use cytology-based testing (Pap testing) for primary screening to detect signs of abnormal cervical cells. However, this is dependent on access and willingness to see a trained clinician for a pelvic exam and cervical cell collection.
HPV testing aims to detect the presence of HPV DNA or RNA. It requires 2 components: adequate sample collection and PCR based testing. Most HPV screening programs are dependent on clinician collected samples, however, self-collected vaginal samples may improve access to testing and thus, overall impact of screening programs.
Many studies have been completed to assess the viability of self-collected samples for HPV testing as compared to clinical collected samples. In a randomized, controlled trial (RCT), women who were attending a clinical for a routine pap test and pelvic exam were included in the study to assess the effectiveness of vaginal self-sampling. The swab self-collection method was found to be non-inferior compared to the clinical specimen. The tampon method of collection, however, was not equivalent.
Results from an Italian pilot study showed self-collected samples demonstrated adequate cellularity (cells stability and health) with the devices tested. HPV testing of self-collected vaginal samples using semi-automated vs automated systems shows good concordance with clinician-collected cervical sample.
CADTH published a Horizon Scan in 2021. (Canada's Drug and Health Technology Agency, 2021) Table 1 is a summary of the evidence they reviewed. There were no safety issues reported for these HPV self-collection devices.
Many studies have assessed the impact of self-collected sampling on increased access and willingness to test in high-risk, underprivileged, or otherwise reluctant populations. One such by Desai et all found that the implementation of self-collect vaginal testing in a Nigerian population, increased screening rates to over 100 women per clinic day, making way for early treatment planning as needed. Reques et al.noted the potential for this approach in an under-served population of France.
Expanding sample collection opportunities beyond existing clinical environments is anticipated to improve access and frequency of HPV screening. Accordingly, cases may be identified earlier in the prognosis, leading to earlier intervention and better health outcomes.
Switch Health has performed a review to identify and evaluate potential collection devices and laboratory protocols for HPV. The Rovers Evalyn®Brush has been selected as the preferred candidate for initial pilot and validation. A 'dry' media was preferred over other liquid media as the use of dry samples eliminates issues related to liquid medium such as spillage, skin irritation, or accidental consumption. Additionally, spillage of the liquid media, by the user or in the lab, can affect the analytical volume for analysis and may impact the accuracy of results. Dry samples can be mailed directly to the lab without any other major considerations (such as Transportation of Dangerous Goods) and at a lower cost, as compared to an equivalent liquid sample.
The Rovers Evalyn® Brush has been designed for self-collection of vaginal samples and may be as accurate as clinician-collected cervical samples. This study will validate the accuracy of the Evalyn® Brush (clinician-collected) with the purpose of making this testing approach available for self-collection in the future.
Expanding sample collection opportunities beyond existing clinical environments to self-collected samples is anticipated to increase testing frequency due to convenience and access. Accordingly, cases may be identified earlier in the prognosis leading to earlier intervention and better health outcomes.
- Conditions
- HPV Infection, Cervical Cancer
- Medical subject headings
- Papillomavirus Infections, Uterine Cervical Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Correlation - Positives
Samples collected via self-collection correlate >95% to those clinician-collected
Measured: Through study completion, an average of 12 weeks
Clinical Correlation - Negatives
Samples collected via self-collection correlate >95% to those clinician-collected
Measured: Through study completion, an average of 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2023
- Study start1 Feb 2023
- Primary completion19 Mar 2024
- Study completion19 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HPV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 344 participants (actual)
Sponsor and investigators
- Lead sponsor
- Switch Health Solutions Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Karam Ramotar, PHD, Principal investigator, Bio-Test Laboratory
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05679141
- Sponsor's protocol ID
- HPV102022
- Status last verified
- Apr 2024
- First submitted
- 7 Dec 2022
- Last updated
- 26 Apr 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits
- ClinicalTrials.gov ID
- NCT05679141
- Acronym / sponsor ID
- HPV102022
- Conditions
- HPV Infection, Cervical Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 344 participants (actual)
- Lead sponsor
- Switch Health Solutions Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Feb 2023 (actual)
- Primary completion
- 19 Mar 2024 (actual)
- Study completion
- 19 Mar 2024 (actual)
- First posted
- 10 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to validate the of the Evalyn®Brush via self-collection to the standard clinician-collected technique using the BD SurePath™ collection vial and Rovers CombiBrush for detection of Human Papillomavirus (HPV). This study will validate the sensitivity and specificity of the Evalyn Brush with the future goal of making this testing approach available for self-collection in the future.
Detailed description
Cervical cancer is one of the most common female cancers in the world. It has been reported that approximately 1300 Canadians are diagnosed with cervical cancer each year. HPV is a common sexually transmitted DNA virus comprised of more than 100 genotypes. Ninety seven percent (97%) of cervical cancer is attributed to 12 strains of HPV and 70% of cervical cancer cases across the world are attributed to 2 specific strains of the virus (HPV 16 and 18).
The current screening practice in Canada is to use cytology-based testing (Pap testing) for primary screening to detect signs of abnormal cervical cells. However, this is dependent on access and willingness to see a trained clinician for a pelvic exam and cervical cell collection.
HPV testing aims to detect the presence of HPV DNA or RNA. It requires 2 components: adequate sample collection and PCR based testing. Most HPV screening programs are dependent on clinician collected samples, however, self-collected vaginal samples may improve access to testing and thus, overall impact of screening programs.
Many studies have been completed to assess the viability of self-collected samples for HPV testing as compared to clinical collected samples. In a randomized, controlled trial (RCT), women who were attending a clinical for a routine pap test and pelvic exam were included in the study to assess the effectiveness of vaginal self-sampling. The swab self-collection method was found to be non-inferior compared to the clinical specimen. The tampon method of collection, however, was not equivalent.
Results from an Italian pilot study showed self-collected samples demonstrated adequate cellularity (cells stability and health) with the devices tested. HPV testing of self-collected vaginal samples using semi-automated vs automated systems shows good concordance with clinician-collected cervical sample.
CADTH published a Horizon Scan in 2021. (Canada's Drug and Health Technology Agency, 2021) Table 1 is a summary of the evidence they reviewed. There were no safety issues reported for these HPV self-collection devices.
Many studies have assessed the impact of self-collected sampling on increased access and willingness to test in high-risk, underprivileged, or otherwise reluctant populations. One such by Desai et all found that the implementation of self-collect vaginal testing in a Nigerian population, increased screening rates to over 100 women per clinic day, making way for early treatment planning as needed. Reques et al.noted the potential for this approach in an under-served population of France.
Expanding sample collection opportunities beyond existing clinical environments is anticipated to improve access and frequency of HPV screening. Accordingly, cases may be identified earlier in the prognosis, leading to earlier intervention and better health outcomes.
Switch Health has performed a review to identify and evaluate potential collection devices and laboratory protocols for HPV. The Rovers Evalyn®Brush has been selected as the preferred candidate for initial pilot and validation. A 'dry' media was preferred over other liquid media as the use of dry samples eliminates issues related to liquid medium such as spillage, skin irritation, or accidental consumption. Additionally, spillage of the liquid media, by the user or in the lab, can affect the analytical volume for analysis and may impact the accuracy of results. Dry samples can be mailed directly to the lab without any other major considerations (such as Transportation of Dangerous Goods) and at a lower cost, as compared to an equivalent liquid sample.
The Rovers Evalyn® Brush has been designed for self-collection of vaginal samples and may be as accurate as clinician-collected cervical samples. This study will validate the accuracy of the Evalyn® Brush (clinician-collected) with the purpose of making this testing approach available for self-collection in the future.
Expanding sample collection opportunities beyond existing clinical environments to self-collected samples is anticipated to increase testing frequency due to convenience and access. Accordingly, cases may be identified earlier in the prognosis leading to earlier intervention and better health outcomes.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 21 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Study population are individuals with a cervix who wish to participate in routine screening for HPV and associated risk for cervical cancers.
Key inclusion criteria (3 listed)
- Participant visiting the study site for a potential OB/GYN purpose
- Participant >= 21 years of age
- Participant has a cervix
Key exclusion criteria (5 listed)
- Currently menstruating
- Currently pregnant or within 3 months following pregnancy
- Utilized vaginal products within past 48 hrs.
- Experiencing any of following symptoms:
- Pain in lower abdomen Fever Unusual or heavy vaginal discharge Pain / bleeding when having intercourse Painful or frequent urination
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Clinical Correlation - Positives
Time frame: Through study completion, an average of 12 weeks
Samples collected via self-collection correlate >95% to those clinician-collected
Clinical Correlation - Negatives
Time frame: Through study completion, an average of 12 weeks
Samples collected via self-collection correlate >95% to those clinician-collected
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Apr 2024.
Related trials for HPV Infection
Active, not recruiting
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
Human Papilloma Virus (HPV) Vaccine
RecruitingPhase 2
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma
RecruitingPhase 2
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
RecruitingObservational study
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
EBV, HSV
Active, not recruiting
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
Cervical Carcinoma, Human Papillomavirus Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Karam Ramotar, PHD principal investigator
Bio-Test Laboratory
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HPV Infection and Cervical Cancer, run by Switch Health Solutions Inc. at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Correlation - Positives (time frame: Through study completion, an average of 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2024.